Reliable biomarkers are required to evaluate and manage pancreatic ductal adenocarcinoma. Circulating tumor cells and circulating tumor DNA are shed into blood and can be relatively easily obtained from minimally invasive liquid biopsies for serial assays and characterization, thereby providing a unique potential for early diagnosis, forecasting disease prognosis, and monitoring of therapeutic response. In this review, we provide an overview of current technologies used to detect circulating tumor cells and circulating tumor DNA and describe recent advances regarding the multiple clinical applications of liquid biopsy in pancreatic ductal adenocarcinoma.

中文翻译：

---

胰腺导管腺癌液体活检：循环肿瘤细胞和循环肿瘤 DNA 的现状。


需要可靠的生物标志物来评估和治疗胰腺导管腺癌。循环肿瘤细胞和循环肿瘤 DNA 流入血液中，可以相对容易地从微创液体活检中获得，用于连续测定和表征，从而为早期诊断、预测疾病预后和监测治疗反应提供独特的潜力。在这篇综述中，我们概述了当前用于检测循环肿瘤细胞和循环肿瘤 DNA 的技术，并描述了液体活检在胰腺导管腺癌中多种临床应用的最新进展。